Company: BUDZ
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001096906-25-000350
Chunk: 6

Company: WEED, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 6
---
 initial extraction with a second round of extractions in July 2017. So far, Industrial Megagenomics, under their agreement
with Sangre have designed, tested, and developed standard operating procedures for efficient DNA isolation and sequencing of Cannabis
genomes. Extensive bioinformatics analysis of repeatable and variable regions has been performed on newly generated DNA, sequencing data
of 30 landrace cultivars and publicly available genomes to identify potential biomarkers to type cannabis plants without the need for
whole genome sequencing. The developed biomarkers were prepared into a package for patenting, however, we are waiting for funding to perform
in-vivo validation. We believe we will be able to finish phase one of the trial within 9-12 months after we have secured sufficient financing.

Under the next phase of
our genomic study, we plan to continue our genetic studies in both the United States and Israel for phase 2, moving directly to clinical
human trials with our wholly owned subsidiary, WEED Israel Cannabis Ltd. under the guidance of Professor Elka Touitou, who has patented
“Delivery systems” to increase bioavailability with Hundreds of formulas she developed at the Hebrew University of Jerusalem
since 1988. In addition, Professor Elka has worked with World Class scientists such as Dr. Raphael Mechoulam and many top echelon scientists
in Israel in Cannabis studies and Human Trials outside of the scope of Patents and Formulas with WEED Inc. In February 2019, Glenn Martin,
our CEO, and WEED Israel Managing Director, Elliot Kwestel, met with Dr. Mechoulam in his office at HUJ to discuss WEED Israel goals of
attaining a high THC cultivar to synthesis for controlled dosing purposes as discussed below. We are ready to begin this phase, but need
additional funding in order to proceed with the planned clinical trials, as well as to continue on to future phases of the genomic study.

6

After the planned clinical
trials, and assuming they are successful, then in Phase 3, we plan for WEED Israel Cannabis Ltd. to utilize our human clinical trials
with continuing genetic studies in Israel, not just at University levels but to include separate studies at Israeli Hospitals and clinics
across Israel from Haifa to Tel Aviv, under Contract Research Organizations (CROs) in order to begin final research & developments
from strain extractions to advance manufacturing, refinement of raw product, scientifically backed, to incorporate into Protocols and
Procedures,